This meta-analysis encompassing 1,850 patients with Hodgkin lymphoma (HL) has found that hematopoietic cell transplantation (HCT) outcomes in HL have improved since 2000. The pooled estimates for 6-month, 1-year, 2-year, and 3-year overall survival (OS) in all studies for all patients were 83 (75-91)%, 68 (62-74)%, 58 (52-64)%, and 50 (41-58)%, respectively. In meta-regression multivariate analysis, study accrual initiation in year 2000 or later was associated with higher 6-month (p=0.012) and 1-year OS (p=0.046). Pre-HCT remission was independently associated with higher 2-year OS (p=0.047) and 1-year relapse-free survival (p=0.016). Non-relapse mortality and relapse rates were also significantly lower, between 5-10% since 2000. The authors noted that “there is no apparent survival plateau, demonstrating the need to improve on current allogeneic HCT strategies in relapsed/refractory HL.”
Rashidi A, et al. Bone Marrow Transplant